Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).
about
Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequencesOral anticoagulant therapy in patients receiving haemodialysis: is it time to abandon it?Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?Capsule commentary on Paradise et al., Outcomes of anticoagulation therapy in patients with mental health conditionsOutcomes of anticoagulation therapy in patients with mental health conditions.The clinical impact of different coagulometers on patient outcomes.Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.Association of quality of life with anticoagulant control in patients with heart failure: the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial.Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional studyUsing highly variable warfarin dosing to identify patients at risk for adverse events.High performing hospitals: a qualitative systematic review of associated factors and practical strategies for improvement.International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillationComparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillationCenter-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation.A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits.Educational Level, Anticoagulation Quality, and Clinical Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study.Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical PracticeEvaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial.Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centreIdentifying the risks of anticoagulation in patients with substance abuseStability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyAnticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience.The business case for quality improvement: oral anticoagulation for atrial fibrillation.Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational StudyPromise of factor Xa inhibition in atrial fibrillation.Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation.Recommendations to prescribe in complex older adults: results of the CRIteria to assess appropriate Medication use among Elderly complex patients (CRIME) project.The caregiver role in thromboprophylaxis management in atrial fibrillation: a literature review.A Practical Guide to Using the Positive Deviance Method in Health Services Research.Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.Evaluation of Direct Oral Anticoagulation Therapy in Heart and Lung Transplant Recipients.Preemptive warfarin dose reduction after initiation of sulfamethoxazole-trimethoprim or metronidazole.Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient managementImpact of point-of-care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study.SAMe-TT2R2 predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI2 experience.Continued Use of Warfarin in Veterans with Atrial Fibrillation After Dementia Diagnosis.Exploring the effect of complex patients on care delivery tasks.
P2860
Q26746062-32E70A26-0529-427E-8BC8-0B8CDB14C190Q26827576-2E21D1D3-AB4A-4B4D-85EA-126AA4D4A632Q27010464-A9CF2490-11A8-4045-9B4F-610CA3E94FFEQ33633105-50DD9868-3FA4-4D88-8114-A4DD1F762F6AQ33633124-F32F89FA-A29E-485D-907E-B8AF93A1A3A0Q33848923-71354725-D90D-456B-B679-4F4B13FD21B5Q34297266-98384A88-9E3F-4457-854B-A47AFB103654Q34633608-949C5F1D-C20C-4208-A598-6A88788E6DB9Q35001891-069215BF-2142-40A8-AD3A-D5B577B6B347Q35196123-14D614E1-BC56-406D-945A-95D9D670F089Q35415257-C26DFECB-472F-40BC-8E2B-F15656C111FDQ35672282-35AF7D44-6315-4518-B6F6-98253F0729B6Q35672988-7783D1B7-C8D2-49D9-A78E-952FA2BCCE2BQ35846377-C0DCAAED-41F1-400D-9AD9-F275A0879CC1Q35860841-3427EE51-2C84-42C0-BAD8-64340C3B6D9CQ35986742-50B7D21D-F6CF-4F63-895C-E980C442D4BCQ36126175-56C52998-EAA8-49BD-9353-32921033D52FQ36168742-BAD9728B-0B03-4A2B-9D3A-915294D7C646Q36195396-75C6A7BD-B836-495A-9350-2A7C4DED07F0Q36527615-C46C1C5C-F1D1-4738-A453-621A10641717Q37203620-AFFD22D5-CE23-4D14-9C03-960AAFDD3BCEQ37240690-6C085A79-9948-462C-A3DE-A66781A8B899Q37620945-2C7B2F05-3F22-4C64-BE93-804C0BEAF51CQ37666333-39505DAF-9AEB-4161-83E7-B2DF4BD29A1DQ37711462-0451C481-030A-4470-833E-3662E0B3EA2AQ37959870-970E6DC5-0B52-4171-AD85-DFCD05AF11E9Q38086125-90554FC4-E14C-418A-90F5-B7F64C492968Q38097972-4AAAA5BD-F7A0-44C0-A631-2EA0629A1BE1Q38162813-6C906BA3-6DC7-4153-B9D5-3445A17EBF7FQ38240097-39C26226-A6D1-47DA-8CBA-7DCEAC42BCE7Q38847933-CFC6B23A-18DE-43C1-BAF7-D94B65921FCFQ38851232-DCE0B77B-0545-4EE4-9F97-118C26ED1EB3Q38935753-12C8F988-4B13-4D88-BBFA-DA407E9772C8Q38946953-74A70852-25D1-4A3C-85BA-08263AA3A190Q39247370-DDAD4400-B22F-48F9-AA7C-5497A19C2580Q39675447-F84FCC2F-9B52-4391-A1E0-1F7FB246CD9CQ40066129-A3B0B42A-BDF2-4DD2-92D5-CF8A014E8E48Q40356300-97807A92-5458-48F6-B69C-11D055CA583CQ40400905-79CDA175-DE9B-4B7F-BD52-0764D63E9985Q40893976-7102DF87-1055-48F4-A029-4A266B1E34FA
P2860
Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Patient characteristics associ ...... prove Anticoagulation (VARIA).
@en
Patient characteristics associ ...... udy to Improve Anticoagulation
@nl
type
label
Patient characteristics associ ...... prove Anticoagulation (VARIA).
@en
Patient characteristics associ ...... udy to Improve Anticoagulation
@nl
prefLabel
Patient characteristics associ ...... prove Anticoagulation (VARIA).
@en
Patient characteristics associ ...... udy to Improve Anticoagulation
@nl
P2093
P2860
P921
P1476
Patient characteristics associ ...... mprove Anticoagulation (VARIA)
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2010.03996.X
P577
2010-10-01T00:00:00Z